EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 52 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab August 11, 2022 FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma February 7, 2022 Girl Scout’s Pink Chair Project Loans Recliners to Women Recovering from... December 21, 2021 The ‘major conditions strategy’: will ministers fail to give cancer the... February 6, 2023 Load more HOT NEWS Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab... EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib NICE recommends pembrolizumab for 1,600 more people with breast cancer New chemotherapy-free treatment for bowel cancer made available in Scotland
